A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction

Exclusion Criteria

• •Active bleeding and/or bleeding diathesis
• •Anemia (hemoglobin \<9 mg/dl)
• •Known thrombocytosis (platelet count \>500,000)
• •Know thrombocytopenia (platelet count \<100,000)
• •NSAIDs (e.g., ibuprofen, naproxen) within 3 days
• •Platelet antagonists other than aspirin and thienopyridines, within 7 days
• •Prior percutaneous coronary intervention or coronary artery bypass grafting
• •Acute myocardial infarction within 3 months
• •Severe valvular heart disease
• •Cardiogenic shock or mechanical circulatory support
• •New York Heart Association (NYHA) Functional Class III or IV heart failure
• •Ejection Fraction \<40%
• •Hypertrophic obstructive cardiomyopathy or severe left ventricular hypertrophy
• •Pregnancy
• •Contraindication to intravenous infusion of adenosine during coronary angiography, due to known hypersensitivity to adenosine, known or suspected bronchoconstrictive or bronchospastic lung disease (severe asthma), second- or third-degree AV block (except in patients with a functioning artificial pacemaker), or sinus node disease, such as sick sinus syndrome or symptomatic bradycardia,
• •Obstructive CAD (≥50% luminal obstruction in ≥1 major epicardial coronary arteries by invasive coronary angiography)
• •Unfavorable coronary artery anatomy for guidewire positioning (as determined by the angiographer or PI)